JP2006305313A - Material for removing albumin-uncombined and glucuronic acid non-conjugation bilirubin - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a removing material restraining adsorption of blood coagulation factor, anticoagulant and albumin by removing albumin-uncombined and glucuronic acid non-conjugation bilirubin, which is an causative agent to a cranial neurapraxia. <P>SOLUTION: This material for removing albumin-uncombined and glucuronic acid non-conjugation bilirubin is a compound formed of base material or support having at least one kind of a hydrogen bonding functional group. <P>COPYRIGHT: (C)2007,JPO&INPIT

Description

  The present invention relates to a removal material that removes albumin non-binding and glucuronic acid non-encapsulated bilirubin excessively present in a body fluid, suppresses coagulation activity, and suppresses adsorption of heparin and albumin.

  In vivo, erythrocytes are metabolized in the reticuloendothelial system of the liver and spleen, and hemoglobin in the erythrocytes changes into bilirubin. In general, the bilirubin produced is water-insoluble (lipid-soluble), so it binds to albumin in the blood and is taken into the liver. In the liver, it becomes water-soluble only after being conjugated with glucuronyltransferase. It is discharged into bile. However, metabolism is slow when the organ function is undeveloped, such as a newborn baby or a low birth weight infant, and when the maternal and fetal blood types (particularly Rh type) are different, fetal erythrocytes due to maternal antibodies due to blood type mismatch When a large amount of hemoglobin is present due to an attack on the liver, the concentration of its metabolite, bilirubin, increases rapidly, resulting in a high bilirubin that cannot keep up with metabolism and excretion and accumulates bilirubin in the blood. Become bloody. Among bilirubin, bilirubin that is not albumin-bound and non-glucuronidated crosses the blood-brain barrier because it is fat-soluble, and when it moves to the brain, bilirubin pigments are deposited mainly in the basal ganglia, and brain neurons are damaged. CNS disorders such as reception, convulsions, posterior bowing tension, and cerebral palsy. Especially in newborns, the causative agent that causes encephalopathy in newborn jaundice was revealed to be albumin-unbound and glucuronide-unconjugated bilirubin. Therefore, it is considered that a material that removes albumin non-binding and glucuronic acid non-conjugated bilirubin is an effective material for treating cranial nerve disorders.

  However, none of the currently available bilirubin-removing materials have been reported to selectively remove albumin-unbound and non-glucuronidated bilirubin, and total bilirubin or non-glucuronidated bilirubin (indirect bilirubin) ) And glucuronic acid-conjugated bilirubin (direct bilirubin) are known only (for example, Patent Document 1, Patent Document 2, and Patent Document 3). A commercially available removal material is an anionic ion exchange resin coated with a blood compatible polymer substance. Since this resin has quaternary ammonium ions, it removes coagulation factors in the blood. Or it has the fault which removes the heparin of the anticoagulant used for extracorporeal circulation, and it is not preferable also from a viewpoint of biocompatibility. Since heparin is negatively charged, it is naturally considered to be adsorbed on quaternary ammonium, and development of a bilirubin removing material that suppresses adsorption of an anticoagulant is desired. Thus, a bilirubin adsorbent (Patent Document 4) in which heparin adsorption is suppressed to 70% or less has been proposed, but actually the heparin adsorption rate is only about 36%, and its performance is insufficient. Furthermore, it is a problem to suppress adsorption of blood coagulation factors in providing a blood purification material. In addition, albumin present in body fluids is an important protein for the living body, and if it is excessively adsorbed and removed, hypoalbuminemia may occur and adversely affect the living body. Therefore, it is desired to develop a removal material that suppresses adsorption of blood coagulation factors and albumin. Up to now, albumin-unbound and glucuronic acid-unconjugated bilirubin can be removed, and further, the adsorption of albumin is suppressed, and the prothrombin time (hereinafter abbreviated as PT), the partially activated thromboplastin time (hereinafter referred to as APTT), which is an indicator of coagulation activity. There are no reports of blood purification materials with a small amount of change.

  A blood purification method using activated carbon is also known, but activated carbon has low selectivity, and it is considered that there are disadvantages due to the adsorption of effective medicines and internal components. Furthermore, exchange blood transfusions are carried out in newborns, but there is a possibility that fever, rash, or viral infection may occur by transfusion of the blood of another person, and only bilirubin is specifically blood with a selective adsorbent material. It would be desirable to be able to remove it from inside.

Further, as an apparatus for removing albumin-bound bilirubin, an apparatus that efficiently removes bilirubin released from albumin using a dissociator that releases bilirubin from albumin such as benzoic acid in the blood in advance has been reported (patent) Reference 3), it is necessary to adsorb a dissociating agent when returning blood to the body, and it is necessary to consider the toxicity of the dissociating agent, and the disadvantage of increased blood volume in patients with low blood volume such as neonates. Yes.
JP-A 63-275351 JP 02-286173 A Japanese Patent No. 0259860 JP 05-329364 A

  Removal material that can remove albumin non-binding and glucuronic acid non-conjugated bilirubin which is a causative agent of cranial nerve injury, suppresses blood coagulation activity, and suppresses adsorption of heparin as an anticoagulant and albumin as a useful substance in living body provide.

  In the present invention, albumin which is a removal material for removing non-albumin and glucuronide-conjugated bilirubin, which contains the functional group capable of forming a hydrogen bond, is a blood coagulation factor, an anticoagulant, and a biologically useful substance It is a material that suppresses the adsorption of. Moreover, it is a body fluid purification column using the material mentioned above.

  According to the present invention, it is possible to remove the albumin non-binding and glucuronic acid non-encapsulated bilirubin which are excessively present in the body fluid, further suppress the blood coagulation activity, and suppress the adsorption of heparin which is an anticoagulant and albumin which is a useful substance of living body. Provide material. This makes it possible to early treat or prevent cranial nerve damage resulting from hyperbilirubinemia.

  The present invention has realized a material for removing albumin non-binding and glucuronic acid non-encapsulating bilirubin having at least one functional group capable of forming a hydrogen bond. The material of the present invention preferably has a change amount of PT, APTT, which is an index of coagulation activity, of 20% or less before and after contact with body fluid, an adsorption rate to heparin of 30% or less, and an adsorption rate to albumin of 20 % Or less. The body fluid refers to blood, plasma, serum, cerebrospinal fluid, amniotic fluid, ascites, pleural effusion and the like.

  As a basic aspect of the present invention, one or more functional groups capable of forming hydrogen bonds are bonded (immobilized) to a substrate (substrate surface).

In the present invention, albumin non-binding and non-glucuronic acid-conjugated bilirubin is a fat-soluble bilirubin that is not bound to albumin in blood and is not glucuronidated in the liver and is free. is there. The removal of non-albumin-bound and glucuronic acid-unconjugated bilirubin refers to the removal of adsorbed and removed albumin-unbound and non-glucuronidated bilirubin from body fluids, and binding of other substances. It also includes losing its activity (inactivation) by, for example. In the measurement of non-albumin-binding and non-glucuronidated bilirubin in the present invention, non-glucuronidated non-glucuronidated which is not subjected to glucuronidation of the liver by using an in vitro system using glucuronid-unconjugated bilirubin. Bilirubin was evaluated. Further, an ultrafiltration membrane having a molecular weight of 50,000 was used for separating albumin-bound and glucuronic acid-unconjugated bilirubin from albumin-unbound and glucuronic acid-unconjugated bilirubin. That is, the molecular weight of human serum albumin is said to be 66300 to 69000, and it was possible to separate albumin-bound and glucuronide-unconjugated bilirubin from albumin-bound and glucuronide-unconjugated bilirubin by such an ultrafiltration membrane. . The quantification of albumin-unbound and glucuronide-unconjugated bilirubin separated from albumin-bound and glucuronide-unconjugated bilirubin was performed using Fuji Dry Chem (Fuji Photo Film Co., Ltd.) by diazotization reaction. .
Until now, conventional bilirubin adsorbents have had the disadvantage of adsorbing heparin and coagulation factors. As a result of examining this phenomenon in detail, it has been found that the conventional bilirubin adsorbent is cationic and therefore adsorbs heparin or coagulation factor having a positive charge due to its electrical characteristics. Therefore, as a result of diligent studies, functional groups capable of forming hydrogen bonds with nonionic bonds as materials that selectively adsorb toxic non-albumin and glucuronate unconjugated bilirubin with low heparin adsorption ability and low coagulation activity. I have found a material with In addition, it is considered effective to reduce hydrophobicity in order to suppress the adsorption ability of proteins such as albumin, which is a useful substance in living organisms. For this purpose, hydrophilic groups such as amino groups and urea bonds are effective. This led to the invention. Although it has been reported that nitrogen-containing heterocyclic compounds adsorb bilirubin, the interaction of this compound with bilirubin is considered to be a bond due to the interaction between π electrons, but the binding force is not sufficient and hydrophilic The nature is also low. For this reason, there is a drawback that the functional separation of bilirubin binding and albumin exclusion is not sufficient. As a result, it was found that a functional group with strong hydrogen bonding has high binding of albumin non-binding and non-glucuronic acid non-encapsulated bilirubin, and further has low coagulation activity, thereby suppressing adsorption of heparin and albumin.

  In the material of the present invention, as an index of the influence on the coagulation system, the amount of change before and after body fluid contact between PT serving as an index of exogenous coagulation factor and APTT serving as an index of endogenous coagulation factor is 20% or less. preferable. In order to provide a blood purification material, it is an essential condition to suppress adsorption of blood coagulation factors, and it is desired that the amount of change is low. The reference value of PT is 10 to 13 seconds and the reference value of APTT is 30 to 45 seconds, respectively, and an extension of 20% or more is considered undesirable. In the present invention, as a result of various investigations, it has become possible to reduce the amount of change in PT and APTT to 20% or less. Such a change amount is calculated by the following equation.

Amount of change (%) = ((PT or APTT value before body fluid contact (seconds) −PT or APPT value (seconds) after body fluid contact) / PT or APTT value (seconds) before body fluid contact) × 100
The functional group capable of forming a hydrogen bond in the present invention is not particularly limited as long as it is a functional group capable of forming a hydrogen bond. For example, a urea bond, a thiourea bond, an amide group, an amino group, a hydroxyl group, a carboxyl group, an aldehyde group A nitrogen-containing functional group, preferably at least one of a urea bond, a thiourea bond or an amide bond, an amino group, a pyridyl group, a pyrimidyl group, and an imidazole group. The functional group capable of forming a hydrogen bond may have a subsequent structure. The structure following the functional group capable of forming a hydrogen bond is not particularly limited, and aliphatic compounds such as propane, hexane, octane and dodecane, and alicyclic compounds such as cyclohexane and cyclopentane can be used. In view of the height, aromatic compounds such as benzene, naphthalene and anthracene are more preferably used. Derivatives such as bromoheptane, chlorocyclohexane, methylbenzene, chlorobenzene, nitrobenzene, diphenylmethane, chloronaphthalene and the like are also preferably used.

  Moreover, in this invention, it is more preferable to have 2 or more types of functional groups which can form a hydrogen bond, and it is preferable that at least 1 type is the above-mentioned nitrogen-containing functional group. In particular, at least one of the nitrogen-containing functional groups is preferably selected from functional groups having a plurality of urea bonds, thiourea bonds, or amide bonds. In this case, different functional groups capable of forming hydrogen bonds may be bonded to the substrate, or another type of functional group capable of forming hydrogen bonds may be bonded to a certain functional group capable of forming hydrogen bonds as a subsequent structure. It is also possible to use such a mode. In particular, as a structure following a urea bond, a thiourea bond or an amide bond, for example, a structure further having a functional group capable of forming a hydrogen bond such as an amino group, a hydroxyl group and a carboxyl group is preferably used. For example, as a structure having an amino group, aminohexane, monomethylaminohexane, dimethylaminohexane, aminooctane, aminododecane, aminodiphenylmethane, 1- (3-aminopropyl) imidazole, 3-amino-1-propene, aminopyridine, Aminobenzenesulfonic acid, tris (2-aminoethyl) amine and the like, and more preferably diaminoethane, diethylenetriamine, triethylenetetramine, tetraethylenepentamine, dipropylenetriamine, polyethyleneimine, N-methyl-2,2′- A compound (polyamine) having a plurality of amino groups such as diaminodiethylamine, N-acetylethylenediamine, 1,2-bis (2-aminoethoxyethane) and the like is used. In addition, examples of the structure having a hydroxyl group include hydroxypropane, 2-ethanolamine, 1,3-diamino-2-hydroxypropane, hydroxybutanone, hydroxybutyric acid, hydroxypyridine, glucose, glucosamine, galactosamine, maltose, cellobiose, sucrose. Monosaccharides such as agarose, cellulose, chitin and chitosan, carbohydrates such as oligosaccharides and polysaccharides, or derivatives thereof can be used. Furthermore, as the structure having a carboxyl group, for example, β-alanine, n-caproic acid, isobutyric acid, γ-amino-β-hydroxybutyric acid and the like can be used. The most preferred embodiment of the present invention is one having both an aromatic compound and a compound capable of forming a hydrogen bond as a structure following a urea, thiourea or amide group.

  Furthermore, polyurea, polythiourea, and polyamide having a plurality of urea bonds, thiourea bonds, and amide bonds in the molecular structure can also be used as the base material or carrier of the material of the present invention. In these cases, any of the above structures can be used as a structure following a urea bond, a thiourea bond, or an amide bond, but most preferably a compound having a hydroxyl group, an amino group, or a carboxyl group (a saccharide or its saccharide). Derivatives), or aromatic compounds.

  Further, the substrate or carrier in the present invention may be any of a monomer, an oligomer, and a polymer, such as polyamide, polymethyl methacrylate, polysulfone, polystyrene, polyethylene, polyvinyl alcohol, and polytetrafluoroethylene, cellulose, Natural polymers including collagen, chitin, chitosan and derivatives thereof are preferably used. That is, it is preferable to introduce a functional group capable of forming a hydrogen bond into these synthetic polymers, natural polymers, and the like that are homopolymerized, copolymerized, or blended. Furthermore, a material in which an inorganic material such as metal, ceramic, or glass is coated with an appropriate polymer as a base material or the surface is directly modified is preferably used. In particular, polystyrene, polysulfone, polymethyl methacrylate, and the like are preferably used because surface modification can be easily performed.

  The material of the present invention can be synthesized by generally known methods. For example, when a urea bond or a thiourea bond is introduced into an aliphatic compound or an aromatic compound, a method of reacting an isocyanate compound or an isothiocyanate derivative with an amino compound can be used. Moreover, when introducing an amide group into an aliphatic compound or an aromatic compound, for example, a method of reacting an acid, acid chloride or acid anhydride with an amino compound can be used. The mixing ratio of the amino compound and the isocyanate, isothiocyanate, acid, acid chloride or acid anhydride can be arbitrarily selected, and is usually 0.1 per mole of isocyanate, isothiocyanate, acid, acid chloride or acid anhydride. ˜5 mol of amino compound is preferably used. Examples of isocyanate or isothiocyanate include ethyl isocyanate, stearyl isocyanate, n-butyl isocyanate, iso-butyl isocyanate, n-propyl isocyanate, methyl isothiocyanate, ethyl isothiocyanate, n-butyl isothiocyanate, benzyl isothiocyanate, hexamethylene diisocyanate. Any of aliphatic isocyanates and isothiocyanates such as cyclohexyl isocyanate, cyclohexyl isothiocyanate and cyclohexyl diisocyanate can be used, but more preferred are phenyl isocyanate, chlorophenyl isocyanate, fluorophenyl isocyanate, bromophenyl isocyanate, nitrophenyl isocyanate. Tolyl isocyanate, methoxyphenyl isocyanate, 1-naphthyl isocyanate, 4,4′-diphenylmethane diisocyanate, 3,3 ′, 5,5′-tetraethyl-4,4′-diisocyanatodiphenylmethane, phenyl isothiocyanate, chlorophenyl isothiocyanate, Aromatic isocyanates or isothiocyanates such as fluorophenyl isothiocyanate, nitrophenyl isothiocyanate, tolyl isothiocyanate, methoxyphenyl isothiocyanate and 1-naphthyl isothiocyanate are used. As the acid chloride, for example, any of aliphatic acid chlorides such as isovaleryl chloride, stearoyl chloride, cyclohexane chloride, 6-chloronicotinyl chloride, etc. can be used, but benzoyl chloride, 3,4-chloride are more preferable. Aromatic acid chlorides such as dichlorobenzoyl, nitrobenzoyl, -4-chlorobenzoyl chloride, -4-trioyl chloride, and benzo- [b] thiophene-2-carbonyl chloride can be used. As the acid anhydride, for example, acetic anhydride, succinic anhydride, phthalic anhydride, benzoic anhydride and the like can be preferably used. Further, the present invention is not limited to the above-described materials, and even in the case of polyurea or polythiourea, for example, a method of reacting a polyisocyanate derivative or polyisothiocyanate derivative with a polyamino compound can be used.

  The amino group of the amino compound used in the present invention may be any of primary amino group, secondary amino group, and tertiary amino group. Examples of the amino compound include ammonia, sec-octylamine, 1- (3-aminopropyl). ) Imidazole, 3-amino-1-propene, aminopyridine, aminobenzenesulfonic acid, tris (2-aminoethyl) amine and the like can be preferably used. Further, polyamino compounds and amino compounds having a hydroxyl group or a carboxyl group that can introduce a group capable of forming a hydrogen bond in addition to a urea bond, a thiourea bond or an amide bond can also be preferably used. Examples of the polyamino compound include diaminoethane, diethylenetriamine, triethylenetetramine, tetraethylenepentamine, dipropylenetriamine, N-methyl-2,2′-diaminodiethylamine, polyethyleneimine, N-acetylethylenediamine, 1,2-bis ( Any of 2-aminoethoxy) ethane and the like can be used. Examples of amino compounds having a hydroxyl group include 2-ethanolamine, 3-propanolamine, 6-hexanolamine, 1,3-diamino-2-hydroxypropane, 2- (2-aminoethoxy) ethanol, 2- (2-amino Ethylamino) aliphatic amines such as ethanol, glucamine, N-methyl-1,3-diaminopropanol, or aromatic amines such as 4-aminophenol, diaminophenol, aminohydroxypyrimidine, diaminohydroxypyrimidine, diaminohydroxypyrazole, Alternatively, amino acids such as serine and tyrosine are used. It is also possible to synthesize an amino compound having a hydroxyl group from a compound having only a hydroxyl group or a compound having only an amino group by reacting epichlorohydrin and an amino compound, or 1,3-dibromo-2-hydroxypropane. It is.

  The same method as described above can also be used when a group capable of forming a hydrogen bond is introduced into a saccharide using a saccharide as a base material. That is, in the case of a carbohydrate having an amino group such as chitosan or glucosamine, the above-described isocyanate, isothiocyanate, acid, acid chloride or acid anhydride can be reacted. In the case of carbohydrates such as cellulose that do not have an amino group, the hydroxyl group of the carbohydrate is activated using epichlorohydrin, tresyl chloride, etc., and then reacted with ammonia or diaminoethane to introduce the amino group. By using this amino group, a group capable of forming a hydrogen bond such as a urea bond, a thiourea bond, and an amide bond can be introduced into the carbohydrate. Examples of amino compounds having a carboxyl group include β-alanine, 4-amino-n-butyric acid, γ-amino-β-hydroxy-n-butyric acid, 6-amino-n-caproic acid, and the like.

  Furthermore, when the material of the present invention is polyamide, for example, a method of polycondensation of polycarboxylic acid and polyamine can be used. In addition, in any of polyurea, polythiourea, and polyamide, the polyurea, polythiothiocyanate, and polythiol are finally introduced by sequentially introducing each functional group without using polyisocyanate, polyisothiocyanate, polycarboxylic acid, or the like. A method of obtaining urea or polyamide is also preferably performed.

In the present invention, when the substrate is an oligomer or polymer, for example, an amino group of a compound having a group capable of forming a hydrogen bond with an oligomer or polymer having an active ester group of a carboxylic acid such as an isocyanate group, a carboxyl group or a succinimide group. A method of reacting a group is preferably used. Further, oligomers or polymers having amino groups, or ammonia, diaminoethane, 1,3-diaminopropane, 1,3-diamino-2-hydroxypropane, 1,2-bis (2-aminoethoxy) ethane, tris (2 -Aminoethyl) amine, oligomers introduced with amino groups by 2- (2-aminoethylamino) ethanol, etc., polymers are reacted with isocyanate derivatives, isothiocyanate derivatives, acids, acid chlorides or acid anhydrides as described above. This is also a preferred method. Moreover, it is preferable to control reaction time and reaction temperature, or to use a protecting group so that an acid chloride or an isocyanate derivative does not react with a group capable of forming a hydrogen bond other than an amino group. Functional groups such as active ester groups of carboxylic acids such as amino groups, isocyanate groups, carboxyl groups or succinimide groups, acid chloride groups and acid anhydride groups can be introduced into the oligomers and polymers as required.
The material of the present invention preferably has a change amount of PT, APTT, which is an index of blood coagulation activity, of 20% or less before and after contact with body fluid, an adsorption rate to heparin of 30% or less, and an adsorption rate to albumin. It is a material for removing albumin non-binding and glucuronic acid non-conjugated bilirubin that is 20% or less. The amount of change in PT and APTT, the adsorption rate for heparin, and albumin can be controlled by, for example, the type and number of functional groups capable of forming hydrogen bonds, the type of subsequent structure, and the like. The adsorption rate for heparin and albumin is determined as follows. That is, it is obtained by contacting a body fluid containing heparin or albumin with a material and measuring the concentration before and after the contact. The concentration of heparin is measured by using a chromogenic synthetic substrate method obtained from a residual factor Xa as a measurement principle using a Behring coagulation system (manufactured by Dade Behring Co., Ltd.). The measurement of albumin concentration is performed using Fuji Dry Chem (Fuji Photo Film Co., Ltd.), and the measurement principle is the bromcresol green method. Further, the respective adsorption rates for heparin and albumin are calculated by the following formulas.

Adsorption rate (%) = ((concentration before body fluid contact−concentration after body fluid contact) / concentration before body fluid contact) × 100
If there are too few functional groups capable of forming hydrogen bonds, it will be difficult to obtain the adsorption performance of bilirubin that is not bound to albumin and unconjugated to glucuronic acid, and the amount of change in PT and APTT, the adsorption rate to heparin, and albumin are the base materials. Or since it is influenced by the carrier, there is a possibility that the performance cannot be satisfied. On the other hand, when the amount is too large, PT and APTT are changed by the functional group capable of forming hydrogen, and heparin and albumin are adsorbed. For example, when polyethyleneimine is used as an amine compound and a functional group having both an amino group and a urea bond is used by further reacting isocyanate, the nitrogen number of the polyethyleneimine is preferably 2 to 10.

  In the present invention, if the amount of the functional group capable of forming a hydrogen bond is too small, it is difficult to obtain the ability to adsorb bilirubin which is not bound to albumin and unconjugated to glucuronic acid, and the amount of change in PT, APTT, heparin Since the adsorption rate for albumin is influenced by the base material or the carrier, there is a possibility that the performance cannot be satisfied. On the other hand, if the amount is too large, PT and APTT are changed by the functional group capable of forming hydrogen, and heparin and albumin are adsorbed. For example, when a functional group capable of forming a hydrogen bond is immobilized by reacting polystyrene having chloroacetamidomethyl as a reactive functional group with tetraethylenepentamine and chlorophenyl isocyanate, the charged amount is tetraethylenepentamine per polystyrene repeating unit. 0.005 to 100.0 mol, chlorophenyl isocyanate 0.005 to 100.0 mol are preferable, tetraethylenepentamine 0.01 to 20.0 mol, and chlorophenyl isocyanate 0.01 to 20.0 mol are more preferable.

  In preparing the material of the present invention, all of the above reaction conditions are not limited, but typically, the reaction temperature is, for example, 0 to 150 ° C., and the reaction time is, for example, 0.1 to 24 hours. . In addition, a reaction solvent is not necessarily required, but it is generally performed in the presence of a solvent. Solvents that can be used include aliphatic hydrocarbons such as methanol, ethanol, isopropyl alcohol, n-butanol, hexane, acetone, N, N-dimethylformamide, and dimethyl sulfoxide, and aromatic hydrocarbons such as benzene, toluene, and xylene. And halogenated hydrocarbons such as dichloromethane, chloroform and chlorobenzene, and ethers such as diethyl ether, tetrahydrofuran and dioxane. The reaction solution after completion of the reaction can be purified by operations such as column chromatography and recrystallization after usual post-treatment such as filtration and concentration, if necessary. In the case of a water-insoluble material, washing with a glass filter or the like is also a preferable method.

  Further, the material of the present invention can be used not only alone, but also can be further fixed to another appropriate base material, or mixed with other materials and used as one column or coating material. The operation such as immobilization or mixing may be performed before the substrate or the carrier is processed into a shape described later, or may be performed after the processing.

  The shape of the substrate or carrier in the present invention is not particularly limited, but when used as a body fluid purification column, beads, fibers (composite fibers, hollow fibers, yarn bundles, yarns, etc.), sponges, nets, Although used as knitted fabric, woven fabric, etc., considering that the surface area is large and the flow resistance is small, fibers (particularly hollow fibers and composite fibers), knitted fabrics, and woven fabrics are preferably used. If the substrate or carrier is a polymer, many of them have fiber-forming ability and can easily be made fibrous. However, if the strength is insufficient for use as a column packing material, Improvements can be made by using a composite fiber, blending with other fibers, blending, weaving, or the like. For example, polystyrene / polypropylene sea-island fiber is a more preferable embodiment because it has easy modification of polystyrene and is easy to handle due to strength reinforcement by polypropylene. In the case of a coating material, a shape such as a knitted fabric or a film is preferable.

  The column filled with the material of the present invention can be used as an extracorporeal circulation column. As the extracorporeal circulation column, the same module as the known extracorporeal circulation column can be used. However, when purifying body fluid of a low-weight infant such as a newborn infant, the priming volume of the column is 50 mL or less. It is desirable to be. This is because the removal material of the present invention is excellent in the adsorption performance of albumin non-binding and glucuronic acid non-encapsulating bilirubin. By using the removal material of the present invention, an extracorporeal circulation column for removing albumin non-binding and glucuronic acid non-encapsulated bilirubin having a priming volume of 50 mL or less was obtained for the first time.

  As a method for extracorporeal circulation, blood derived outside the body may be directly passed through a column, or may be used in combination with a plasma separation membrane or the like.

  Hereinafter, the present invention will be described in detail using examples, but the content of the invention is not limited to the examples.

<Example 1>
An in vitro albumin non-binding and glucuronic acid non-conjugated bilirubin removal test (1) was performed.
Sea-island type composite fiber (strength: 1.0 g / d, elongation: 47.7%, thickness: 132 denier, island) consisting of 65 parts by weight sea component (polystyrene) and 35 parts by weight island component (polypropylene) 16) 30 g was reacted with a mixed solution of 60 g of N-methylol-α-chloroacetamide, 400 g of nitrobenzene, 400 g of 98% by mass sulfuric acid and 0.86 g of paraformaldehyde at 20 ° C. for 1 hour. Thereafter, the fiber was washed with nitrobenzene, then the reaction was stopped with methanol, and further washed with methanol to obtain α-chloroacetamidomethylated crosslinked polystyrene fiber (hereinafter abbreviated as AMPSt fiber).

Next, the AMPSt fiber was added to 500 ml of dimethyl sulfoxide (hereinafter abbreviated as DMSO) in which 5.0 g of tetraethylenepentamine was dissolved, and the reaction was carried out at 30 ° C. for 3 hours. Further, the fiber was added to a solution of 1000 ml of DMSO in which 1.9 g of 4-chlorophenyl isocyanate was dissolved, and the reaction was carried out at 30 ° C. for 1 hour. Thereafter, the glass filter was washed with 1000 ml of DMSO and further with 1000 ml of distilled water to obtain AMPSt fibers (abbreviated as UAMP fibers) into which urea bonds were introduced.
Using the prepared UAMP fiber, a test for removing bilirubin that was not bound to albumin and unconjugated to glucuronic acid was performed. As the bilirubin, bilirubin unconjugated with glucuronic acid was used. In the bilirubin solution preparation method, since bilirubin is insoluble in water, it was first dissolved in 100 mM sodium hydroxide. Furthermore, since albumin is present in human body fluid, it was dissolved in a 4% human serum albumin solution. The concentration of bilirubin in the adsorbed solution was 300 mg / mL. Next, 30 mg of UAMP fiber was added to 1 mL of this adsorbed solution, and an adsorption reaction was performed while swirling at 37 ° C. for 2 hours. Next, the bilirubin solution before and after the adsorption is separated by an ultrafiltration membrane having a molecular weight of 50,000, and the adsorption rate is calculated by separating it into an albumin-unbound and glucuronic acid-unconjugated bilirubin solution and an albumin-bound and glucuronic acid unconjugated bilirubin solution. did. Further, the adsorption rate was calculated as follows.

Adsorption rate (%) = ((concentration before body fluid contact−concentration after body fluid contact) / concentration before body fluid contact) × 100
The measurement of the bilirubin concentration was performed by using a Fuji Dry Chem (Fuji Photo Film Co., Ltd.) by a diazotization reaction. Moreover, the albumin content of each solution was determined using Fuji Dry Chem (Fuji Photo Film Co., Ltd.) by the bromcresol green method. The results are shown in Table 1.

  From the above results, it was shown that UAMP fibers having a urea bond selectively adsorbed and removed albumin-unbound and glucuronide-unconjugated bilirubin at a high rate.

<Example 2>
An in vitro albumin non-binding and glucuronic acid non-conjugated bilirubin removal test (2) was performed.
Sea-island type composite fiber (strength: 1.0 g / d, elongation: 47.7%, thickness: 132 denier, island) consisting of 65 parts by weight sea component (polystyrene) and 35 parts by weight island component (polypropylene) 16) 30 g was reacted with a mixed solution of 60 g of N-methylol-α-chloroacetamide, 400 g of nitrobenzene, 400 g of 98% by mass sulfuric acid and 0.86 g of paraformaldehyde at 20 ° C. for 1 hour. Thereafter, the fiber was washed with nitrobenzene, then the reaction was stopped with methanol, and further washed with methanol to obtain α-chloroacetamidomethylated crosslinked polystyrene fiber (hereinafter abbreviated as AMPSt fiber).

  Next, the AMPSt fiber was added to 500 ml of dimethyl sulfoxide (hereinafter abbreviated as DMSO) in which 9.6 g of 2-amino-pyrimidine was dissolved, and the reaction was performed at 30 ° C. for 3 hours. Thereafter, the plate was washed with 1000 ml of DMSO on a glass filter, and further washed with 1000 ml of distilled water to obtain AMPSt fibers (abbreviated as APAMP fibers) into which aminopyrimidine was introduced. Using the prepared APAMP fiber, a test for removing bilirubin that was not bound to albumin and unconjugated to glucuronic acid was performed. The test method was the same as the method of Example 1. The results are shown in Table 2. From the above results, it was shown that the APAMP fiber having an aminopyrimidine group selectively adsorbs and removes albumin-unbound and glucuronic acid-unconjugated bilirubin at a high rate.

<Example 3>
In vitro PT and APTT variation measurement tests and heparin and albumin adsorption tests were performed. Using the UAMP fiber and APAMP fiber produced in Examples 1 and 2, a test for measuring changes in PT and APTT, which are indicators of blood coagulation activity, and an adsorption test for heparin (anticoagulant) and albumin were performed. PT, APTT variation measurement test and albumin adsorption test were performed on 1 mL of normal human plasma treated with 30 mg of UAMP fiber with 3.8 mass% sodium citrate, and heparin adsorption test was performed on 30 mg of UAMP fiber and APAMP fiber in 1 mL of normal human whole blood. Were added, and an adsorption experiment was conducted while swirling and stirring at 37 ° C. for 1 hour. For PT and APTT, the rate of change was determined from the time before and after adsorption, and for heparin and albumin, the rate of adsorption was determined from the concentration before and after adsorption. The rate of change and the adsorption rate were calculated as follows.

Change rate or adsorption rate (%) = ((concentration before body fluid contact−concentration after body fluid contact) / concentration before body fluid contact) × 100
For the measurement, PT is a quick one-step method (scattering photometry), APTT is a Langdell method (scattering photometry), and heparin is a Behring coagulation system (manufactured by Dade Bering Co., Ltd.). In the chromogenic synthetic substrate method determined from the residual amount of Xa, albumin was measured by bromcresol green method using Fuji Dry Chem (manufactured by Fuji Photo Film Co., Ltd.). The results are shown in Table 3 (UAMP fiber) and Table 4 (APAMP fiber). From the above results, the adsorbed material by UAMP fiber and APAMP fiber has an extension rate of PT and APTT of 20% or less before and after contact, an adsorption rate to heparin of 30% or less, and an adsorption rate to albumin of 20%. It was shown that:

<Example 4>
An in vitro albumin non-binding and glucuronic acid non-conjugated bilirubin perfusion removal test was performed.
The UAMP fiber shown in Example 1 was filled in a 10 mL priming volume blood purification column, washed with RO water (reverse osmosis membrane filtered water), then filled with physiological saline, and γ-ray sterilization of the fiber in the column was performed. . Next, a circuit of 10 mL of priming volume was connected to the column, and 500 mL of physiological saline was poured using a peristaltic pump to wash the column. Thereafter, a perfusion removal test was performed using a bilirubin solution not bound to albumin and unconjugated to glucuronic acid. The bilirubin used was a bilirubin that was not conjugated with glucuronic acid, and the method for preparing a bilirubin solution that was not bound to albumin and that was not conjugated to glucuronic acid was as shown in Example 1. The temperature and time conditions during perfusion were 37 ° C. and 5 hours, and the sampling time was before the start of perfusion, 1 hour, 2 hours, 3 hours, 4 hours and 5 hours after the start of perfusion. The sampled solution was separated with an ultrafiltration membrane having a molecular weight of 50,000, and divided into an albumin-unbound and glucuronic acid-unconjugated bilirubin solution and an albumin-bound and glucuronic acid-unconjugated bilirubin solution, and the adsorption rate was calculated.

  For the measurement of the bilirubin concentration, the total bilirubin concentration was measured using Fuji Dry Chem (Fuji Photo Film Co., Ltd.). The results are shown in Tables 6 and 7.

  From the above results, it was shown that albumin-unbound and glucuronic acid-unconjugated bilirubin can be adsorbed and removed at a high rate by filling a blood purification column with UAMP fiber having urea bond and perfusing.

<Comparative Example 1>
An in vitro albumin non-binding and glucuronic acid non-conjugated bilirubin removal test (3) was performed.
Sea-island type composite fiber (strength: 1.0 g / d, elongation: 47.7%, thickness: 132 denier, island) consisting of 65 parts by weight sea component (polystyrene) and 35 parts by weight island component (polypropylene) 16), an albumin non-binding and glucuronic acid non-conjugated bilirubin removal test was conducted. As the bilirubin, bilirubin unconjugated with glucuronic acid was used. Since albumin is present in human body fluids, bilirubin was dissolved with a 4% human serum albumin solution. The test method was the same as that of Example 1. The results are shown in Table 5.
From the above results, it was shown that UAMP fibers in which urea bonds were introduced via polystyrene and polypropylene sea-island type composite fibers via amidomethylation and TEPA formation were able to adsorb and remove albumin-unbound and glucuronide-unconjugated bilirubin at a high rate. .

Claims (10)

  A material for removing bilirubin which is not bound to albumin and unconjugated to glucuronic acid, which is a compound comprising a base material or a carrier having at least one functional group capable of forming a hydrogen bond.   Even when contacted with a body fluid, the amount of change in prothrombin time and partially activated thromboplastin time, which are coagulation activities, is 20% or less before and after contact, the adsorption rate to heparin is 30% or less, and the adsorption rate to albumin The material for removing non-albumin-bound and glucuronic acid-unconjugated bilirubin according to claim 1, wherein is 20% or less.   The albumin non-binding and glucuronic acid non-conjugation according to claim 1 or 2, wherein the functional group capable of forming a hydrogen bond has two or more types, and at least one of the functional groups is a nitrogen-containing functional group. The material that removes bilirubin.   The albumin non-bonding according to claim 3, wherein the nitrogen-containing functional group is at least one selected from the group consisting of a urea bond, a thiourea bond, an amide bond, an amino group, a pyridyl group, a pyrimidyl group, and an imidazole group. In addition, a material for removing glucuronic acid-unconjugated bilirubin.   4. The albumin-unbound and glucuronide-unconjugated bilirubin is removed according to claim 3, wherein at least one of the nitrogen-containing functional groups is selected from functional groups having a plurality of urea bonds, thiourea bonds or amide bonds. material.   The non-albumin-bonded compound according to any one of claims 1 to 5, wherein the compound comprising a base material or a carrier having at least one functional group capable of forming a hydrogen bond is selected from polyurea, polythiourea, and polyamide. Material that removes glucuronic acid-unconjugated bilirubin.   The material for removing bilirubin which is not bound to albumin and unconjugated to glucuronic acid according to any one of claims 1 to 6, which is a body fluid purification material.   The substrate or carrier has any form of fiber, knitted fabric, woven fabric, bead, sponge, or net, and is composed of a synthetic polymer material or a natural polymer material. The material which removes the albumin non-binding and glucuronic acid non-conjugated bilirubin according to any one of claims 1 to 7.   A body fluid purification column capable of extracorporeal circulation, which is filled with a material for removing bilirubin not bound to albumin and unconjugated to glucuronic acid according to any one of claims 1 to 8.   The body fluid purification column capable of extracorporeal circulation according to claim 9, wherein the priming volume is 50 mL or less.